Undifferentiated pleomorphic sarcoma
Therapeutic area
Oncology
Rare disease
Yes
- Definition
- An undifferentiated soft tissue sarcoma characterized by the presence of a pleomorphic malignant cellular infiltrate. It is also known as malignant fibrous histiocytoma.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Undifferentiated pleomorphic sarcoma
- Therapeutic area
- Oncology
- undifferentiated pleomorphic sarcoma
- MFH
- Storiform-pleomorphic MFH
- Storiform-pleomorphic fibrous histiocytoma
- Storiform-pleomorphic malignant fibrous histiocytoma
- UPS
- Unclassified Pleomorphic sarcoma (formerly "MFH")
- Unclassified Pleomorphic sarcoma (formerly "malignant fibrous histiocytoma")
- adult malignant fibrous histiocytoma
- adult unclassified pleomorphic sarcoma
- adult undifferentiated pleomorphic sarcoma
- fibrous histiocytoma, malignant
- fibrous histiocytoma, malignant (morphologic abnormality)
- fibroxanthosarcoma
- fibroxanthosarcoma (morphologic abnormality)
- histiocytoma, fibrous, malignant
- malignant fibrous cytoma
- malignant fibrous histiocytoma
- malignant fibrous histiocytoma of soft tissue and bone
- malignant fibrous histiocytoma of the soft tissue and bone
- malignant fibroxanthoma
- unclassified pleomorphic sarcoma
- undifferentiated pleomorphic sarcoma
- undifferentiated pleomorphic soft tissue sarcoma
- malignant fibrohistiocytic tumors
And 2 more, listed on the interactive page.
- Severity
- Severe
- Oncology
- Rheumatology
- MONDO ID
- MONDO:0002142
- Parent condition
- MONDO:0005509
Related records
Broader conditions (23)
- Bone cancer
- Bone disorder
- Bone neoplasm
- Bone sarcoma
- Cancer
- Cancer or benign tumor
- Connective and soft tissue neoplasm
- Connective tissue disorder
- Connective tissue neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Histiocytoma
- Human disease
- Malignant soft tissue neoplasm
- Musculoskeletal system cancer
- Musculoskeletal system disorder
- Neoplasm
- Neoplastic disease or syndrome
- Sarcoma
Narrower conditions (3)
- Cutaneous undifferentiated pleomorphic sarcoma
- Malignant giant cell tumor of soft parts
- Undifferentiated pleomorphic sarcoma, inflammatory variant
Trials (90)
- A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
- A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
- A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
- A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma
- A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma
- A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma
- A Study of LY3435151 in Participants With Solid Tumors
- A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg
- A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
- ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
- Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
- Autologous Dendritic Cell Vaccine in Patients With Soft Tissue Sarcoma
- AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
- BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
- Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma
- Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
- Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma
- CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
- Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery
- Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
Drugs in development (8)
- Catequentinib Phase 2
- Ipilimumab Phase 2
- Nivolumab Phase 2
- Palbociclib Phase 1
- Pembrolizumab Phase 1
- Samrotamab vedotin Phase 1
- Sintilimab Phase 2
- Toripalimab Phase 2